Considering COX-2 as one of the crucial regulators of tumor angiogenesis and TAMs as a main source of COX-2 in the TME, we suggested that the administration of celecoxib in combination with RTK inhibitors can be efficient therapeutic strategy for cancer treatment. Here, PTGS2 is linked to cancer.